scholarly journals Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab

Author(s):  
A. Egeberg ◽  
L. Iversen ◽  
A. B. Kimball ◽  
S. Kelly ◽  
E. Grace ◽  
...  
2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Kavitha Mohanasundaram ◽  
Sham Santhanam ◽  
Hema Murugesan ◽  
Thilagavthy Nambi ◽  
Raja Natarajan

2021 ◽  
pp. jrheum.201627
Author(s):  
Rodrigo García Salinas ◽  
Einer Sanchez Prado ◽  
Santiago Ruta

Reported data of axial involvement in psoriatic arthritis (PsA) are variable (25–70%). This variability is mainly linked to different ways of defining this feature. Gladman1 established that the prevalence of axial involvement in PsA was close to 50% and that it is associated with HLA-B27. Likewise, psoriasis (PsO) spondylitis, unlike ankylosing spondylitis (AS), is characterized by not having a greater preponderance of the male sex, greater skin involvement, and a less severe course.2


2020 ◽  
Vol 158 (6) ◽  
pp. S-442
Author(s):  
Sheri Volger ◽  
Ilia Tikhonov ◽  
Connie Lin ◽  
Christopher D. O'Brien ◽  
Colleen W. Marano ◽  
...  

2019 ◽  
Vol 39 (9) ◽  
pp. 1595-1605 ◽  
Author(s):  
Sanja Milutinovic ◽  
Kristina Veljkovic ◽  
Maja Zlatanovic ◽  
Goran Radunovic ◽  
Nemanja Damjanov

2014 ◽  
Vol 41 (11) ◽  
pp. 2286-2289 ◽  
Author(s):  
Peter Nash ◽  
Ennio Lubrano ◽  
Alberto Cauli ◽  
William J. Taylor ◽  
Ignazio Olivieri ◽  
...  

Axial involvement in patients with psoriatic arthritis (PsA) remains common and can be defined in terms of spinal disease alone or in combination with peripheral manifestations. Diagnosis is based upon inflammatory spinal symptoms or the presence of radiological sacroiliitis and other radiographic signs of spondylitis, or by criteria for axial spondyloarthritis (SpA) defined by ASAS (Assessment of SpondyloArthritis International Society). Although recent data are scarce for efficacy of traditional therapies for axial disease (e.g., nonsteroidal antiinflammatory drugs, methotrexate, etc.), limited data are available for targeted biologics and novel agents. We identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. This review is an update of the axial PsA section of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).


Sign in / Sign up

Export Citation Format

Share Document